Newsroom

CAR-T therapy has promise but manufacturing is slow and expensive. In this article, ScaleReady's Josh Ludwig suggests CAR-T manufacturing can learn from the auto industry's assembly-line approach to improve efficiency and make these therapies more accessible.

In this edition of the Pharma's Almanac quarterly roundtable questionnaire, industry experts, including Josh Ludwig, Global Director of ScaleReady, discuss the increasing pressure to reduce time-to-market. The share strategies to accelerate product development and commercialization without compromising quality.

In this edition of the Pharma's Almanac quarterly roundtable questionnaire, industry experts, including Josh Ludwig, Global Director of ScaleReady, discuss how pharmaceutical and biopharmaceutical companies can demonstrate their commitment to ESG principles in manufacturing.

Key figures at Phacilitate’s Advanced Therapies Week emphasized the power of sharing knowledge to create standardized, scalable processes in cell and gene therapy manufacturing. ScaleReady is proud to embrace this approach, especially in our partnership with Luminary Therapeutics.

Decentralized manufacturing models, where therapies are produced closer to the patient show promise. But the path from research to this decentralized model, while maintaining rigorous Good Manufacturing Practice (GMP) compliance, is anything but easy. In a recent panel discussion, Josh Ludwig shed light on this complex transition.

While cell and gene therapy represent a captivating frontier, ongoing innovation and adaptation to Industry 4.0 principles are essential for progress. In this feature, experts, including Josh Ludwig, Global Director of ScaleReady, delve into the definitions of Industry 4.0 and its implications for the present and future of cell and gene therapy manufacturing.

The upcoming year promises significant changes driven by historic successes and economic challenges in 2023. Notable events mark the industry's current juncture of innovation and adjustment. Industry leaders, including ScaleReady's Josh Ludwig, predict trends for 2024, including the transformative impact of AI in drug development and key regulatory changes to monitor.

During Advanced Therapies Week (ATW) 2024, Drug Discovery World heard from attendees and experts, including ScaleReady's Josh Ludwig, about the obstacles the sector needs to overcome to succeed. 

The high cost of CAR-T therapy has been a major barrier to its widespread adoption. However, a new study suggests that a more standardized, modular production approach could help to reduce costs and make this life-saving treatment more accessible to patients.

In this Genetic Engineering & Biotechnology News article, "Downstream Trends and Challenges," the author discusses the increasing complexity and challenges facing manufacturers today. ScaleReady is mentioned as a joint venture designed to better serve cell therapy developers with scaleable, flexible platforms from established partners.